Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $167.38M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 2.04M
Average 0.45M
IVA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Inventiva S.A.NASDAQ: IVA
EBITDA · Q4 FY2025 · quarter ended Dec 2025
EBITDA remains negative
Q4 FY2025 EBITDA was -€77.74M, compared with -€114.71M a year earlier.
Context
- EBITDA amounted to 2858.6% of revenue in FY2025, up 1048.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of -€116.53M (+9.1%) for the fiscal year ending Dec 2026, a slowdown from the +23.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -€77.74M— QoQ
- Last fiscal yearDec 2025
- -€128.15M+23.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.2% | — | — |
| 1 year | +23.0% | +9.1% | -14.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- (128.15M) EUR
- Year-over-year change
- +23.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (128.15M) | +23.0% |
| FY2024 | 2024-12-31 | (166.53M) | -63.2% |
| FY2023 | 2023-12-31 | (102.04M) | -81.3% |
| FY2022 | 2022-12-31 | (56.29M) | -6.7% |
| FY2021 | 2021-12-31 | (52.76M) | — |
EBITDA vs competitors
How IVA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.0% is the 4th highest of 10, against a peer median of +20.1%.
- EBITDA amounts to 2858.6% of revenue for IVA, versus a peer median of 999.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M USD | -75.7% | — | — |
| LTM Mar 2026 | -$46.56M USD | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$50.77M USD | +11.7% | — | — | |
| LTM Mar 2026 | -$52.72M USD | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$75.47M USD | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$75.72M USD | +45.7% | — | 135.5% | |
| LTM Mar 2026 | -$84.35M USD | -214.9% | — | 142957.6% | |
| LTM Mar 2026 | -$111.97M USD | +23.4% | — | 999.5% | |
| FY2025 | -€128.15M EUR | +23.0% | — | 2858.6% | |
| LTM Mar 2026 | -$158.55M USD | -341.7% | — | 8932.3% | |
| Peer median (excluding IVA) | — | +20.1% | — | 999.5% | |
Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.19M | 12.18M | 17.48M | 9.2M | 4.48M |
| Cost of Revenue | 1.02M | 995K | (23K) | 3.88M | 2.8M |
| Gross Profit | 4.19M | 17.06M | 17.5M | 9.2M | 1.51M |
| Gross Margin | 100.0% | 140.1% | 100.1% | 100.0% | 33.7% |
| Research & Development | 48.45M | 60.47M | 110.01M | 90.88M | 83.61M |
| Selling, General & Admin | 11.52M | 15.5M | 15.61M | 17.1M | 53.89M |
| Operating Expenses | 56.31M | 74.17M | 120.19M | 106.76M | 137.37M |
| Depreciation & Amortization | 858K | 870K | 2.6M | 5.2M | 2.8M |
| EBITDA | (52.76M) | (56.29M) | (102.04M) | (166.53M) | (128.15M) |
| EBITDA Margin | -1258.0% | -462.2% | -583.9% | -1810.4% | -2858.6% |
| Operating Income | (52.11M) | (57.11M) | (102.71M) | (97.56M) | (130.95M) |
| Operating Margin | -1242.6% | -468.9% | -587.7% | -1060.6% | -2921.0% |
| Interest Income | 57K | 390K | 945K | 1.14M | 2.83M |
| Interest Expense | 138K | 707K | 5.18M | 12.18M | 32.3M |
| Other Income / Expenses | 2.84M | 2.82M | (7.11M) | (86.34M) | (211.38M) |
| Income Before Tax | (49.27M) | (54.29M) | (109.82M) | (183.9M) | (342.33M) |
| Pre-Tax Margin | -1174.8% | -445.8% | -628.4% | -1999.4% | -7636.1% |
| Income Tax Expense | 364K | (20K) | 607K | 313K | 22K |
| Net Income | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (340.16M) |
| Net Margin | -1183.5% | -445.6% | -631.8% | -2002.7% | -7587.8% |
| EPS (Basic) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| EPS (Diluted) | (1.27) | (1.31) | (2.43) | (3.54) | (1.82) |
| Weighted Avg Shares | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
| Weighted Avg Shares (Diluted) | 39.17M | 41.45M | 45.35M | 51.98M | 186.8M |
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.